# US 6,727,062 B1 · Identification of target structures E.G. in vivo selection method for a phage library

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,062 B1
- Document ID: US6727062B1
- Status: Granted
- Kind: B1
- Application number: 09/365,241
- Filed: 1999-07-30
- Granted: 2004-04-27
- Earliest claimed: 1997-01-31
- Assignees: Active Biotech AB
- Inventors: Thomas Brodin; Jesper Tordsson; Pia Jasmine Karlström
- Web page: https://patentgrep.com/patent/US6727062B1

## CPC

- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C07K 1/047: {Simultaneous synthesis of different peptide species; Peptide libraries}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3053: {Skin, nerves, brain}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a selection method and the products identified using the selection method which includes the steps of identifying one or more binding structures to a target structure using one or more libraries. The method includes the steps of reacting a first library with the displayed target structure to bind some of the binding structures to the displayed target structure, separating the displayed target structure and bound binding structures from unbound binding structures, and recovering bound or unbound binding structures. The bound or unbound binding structures can be amplified to create enriched libraries of binding structures. Binding structures thus identified are directed to target structures which are displayed in vivo and/or in situ.

## Claims

### Claim 1

A method to acquire a monoclonal antibody or scFv/Fab antibody fragment against a target structure comprising the steps of:
(A) exposing a first mounted tissue to an initial antibody library or scFv/Fab antibody fragment library, members of the antibody library or members of scFv/Fab antibody fragment library, is linked to a filamentous phage, a virus, a polysome, or a coded bead comprising an antibody- or scFv/Fab antibody fragment-encoding sequence;
(B) eluting directly from the first mounted tissue unbound elements, wherein the unbound elements comprise a first enriched library; and/or
recovering a second enriched library comprising the filamentous phage, virus, polysome, or coded bead cleaved from bound elements in the first mounted tissue by cleaving the bound elements from the filamentous phage, virus, polysome, or coded bead;
(C) amplifying either the first or second enriched libraries;
(D) exposing the first or second enriched libraries to a second mounted tissue, wherein the second mounted tissue represents a different physiological or pathological state than the first mounted tissue;
(E) eluting directly from the second mounted tissue unbound elements of the second enriched library from the second mounted tissue, wherein the unbound elements comprise a third enriched library; and/or
recovering a fourth enriched library comprising a filamentous phage, virus, polysome, or coded bead of the first enriched library bound to the second mounted tissue section by cleaving the bound elements from the filamentous phage, virus, polysome, or coded bead of the first enriched library;
(F) amplifying either the third or fourth enriched libraries; and
(G) isolating the monoclonal antibody or scFv/Fab antibody fragment from either the third or fourth enriched libraries.

### Claim 2 (depends on 1)

The method of claim 1 further comprising repeating steps (A) to (G).

### Claim 3 (depends on 1)

The method of claim 1 further comprising repeating steps (D) to (G).

### Claim 4 (depends on 1)

The method of claim 1 further comprising repeating steps (A) to (C).

### Claim 5 (depends on 1)

The method of claim 1 further comprising the step of comparing binding of the antibody or scFv/Fab antibody fragment to a target structure in the first mounted tissue to binding of the antibody or scFv/Fab fragment to the target structure in the second mounted tissue.

### Claim 6 (depends on 5)

The method of claim 5, wherein the binding is specific for a physiological process.

### Claim 7 (depends on 6)

The method of claim 6, wherein the physiological process is a pathological process, cell development and differentiation, tissue development and differentiation, a drug response, or a naturally occurring degradation process.

### Claim 8 (depends on 7)

The method of claim 7, wherein the pathological process is inflammation, a secondary tumor deposit or tumor vasculature.

### Claim 9 (depends on 1)

The method of claim 1, wherein the target structure of the first and second mounted tissues is extracellular or intracellular.

### Claim 10 (depends on 9)

The method of claim 9, wherein the intracellular target structure is located intranuclear of a nuclear membrane.

### Claim 11 (depends on 9)

The method of claim 9, wherein the extracellular target structure is on the cell surface or a molecule released from a cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cell is a tumor cell.

### Claim 13 (depends on 11)

The method of claim 11, wherein the molecule is released actively or passively.

### Claim 14 (depends on 5)

The method of claim 5, wherein the target structure is a ligand, a receptor, an adhesion molecule, a matrix associated molecule or a combination thereof.

### Claim 15 (depends on 5)

The method of claim 5, wherein the target structure is a protein, a carbohydrate, a nucleic acid or a lipid.

### Claim 16 (depends on 1)

The method of claim 1, wherein the first or second mounted tissue is a frozen tissue section or a fixed tissue section.

### Claim 17 (depends on 1)

The method of claim 1, wherein the first or second mounted tissue is pretreated with an enzyme or a chemical.

### Claim 18 (depends on 17)

The method of claim 17, wherein the enzyme pre-treatment is performed with a protease, a polysaccharase, a ribonuclease, a nuclease or a combination thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the tissue is bone marrow cells, lymph cells, sperm cells or cells from cerebrospinal fluid.

### Claim 20 (depends on 1)

The method of claim 1, wherein the initial library is a combinatorial library.

### Claim 21 (depends on 20)

The method of claim 20, wherein the combinatorial library is a naive antibody library, a synthetic antibody library, a semi-synthetic antibody library, or a combinatorial library produced by immunizing against one or more target structures.

### Claim 22 (depends on 1)

The method of claim 1, wherein step (C) comprises amplifying the bound or unbound elements using bacterial cells, PCR synthesis or chemical synthesis.

### Claim 23 (depends on 1)

The method of claim 1, wherein the monoclonal antibody or scFv/Fab antibody fragment of the initial library is linked to a filamentous phage or virus.

### Claim 24 (depends on 1)

The method of claim 1, wherein the the antibody or scFv/Fab antibody fragment or the initial library is linked to a polysome or a coded bead.

### Claim 25 (depends on 23)

The method of claim 23, wherein the the antibody or scFv/Fab antibody fragment of the initial library is linked to a filamentous phage.

### Claim 26 (depends on 25)

The method of claim 25, wherein the filamentous phage is M13.

### Claim 27 (depends on 1)

The method of claim 1, wherein the bound elements recovered in steps (B) or (E) comprise a phage and maintain amplification ability.

### Claim 28 (depends on 26)

The method of claim 26, wherein the cleaving of steps (B) or (E) occurs between minor coat protein pIII and the monoclonal antibody or scFV/Fab antibody fragment.

### Claim 29 (depends on 1)

The method of claim 1, wherein the cleaving of steps (B) or (E) is a proteolytic cleavage and occurs at a protease recognition site.

### Claim 30 (depends on 29)

The method of claim 29, wherein the proteolytic cleavage is performed by Ala64-subtilisin or blood clotting factor Xa.

### Claim 31 (depends on 1)

The method of claim 1, wherein the eluting of steps (B) or (E) is a chemical elution.

### Claim 32 (depends on 31)

The method of claim 31, wherein the chemical elution is an acid or alkaline elution.

### Claim 33 (depends on 32)

The method of claim 32, wherein the alkaline elution is triethylamine elution.

### Claim 34 (depends on 1)

The method of claim 1, further comprising repeating steps (A) and (B) to negatively enrich the unbound elements of the first enriched library or to positively enrich the bound elements of the second enriched library.
